PharmaTutor (March - 2017)
ISSN: 2347 - 7881
(Volume 5, Issue 3)
Received On: 29/10/2016; Accepted On: 22/11/2016; Published On: 01/03/2017
AUTHORS:
Manish Patil 1, Harsha D Jani1, Suleman S Khoja 2, Narmin A Pirani 3, Shamim S Khoja 3
1Department of Quality Assurance,
Shivam Pharmaceutical Studies and Research Centre, Anand, Gujarat, India.
2Resource person in pharmaceutical quality assurance and Audit Compliance, Vapi, Gujarat, India
3Registered Pharmacist, Gujarat, India
* manishpatil3194@gmail.com
ABSTRACT: This review article presents the pharmacology of combined Metformin hydrochloride and Teneligliptin hydrobromide hydrate is effective on type 2 Diabetes Mellitus. Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Teneligliptin, a third generation DipeptidylPeptidase-4 (DPP-4) inhibitor exhibits unique “J shaped” structure with “anchor-lock domain” mechanism which provides potent & long duration of action. The addition of teneligliptin once daily to Metformin was effective and generally well tolerated in Korean patients with type 2 diabetes. The mechanism of Metformin hydrochloride and teneligliptin hydrobromide hydrate is quite different. The main objective of this review article is to provide pharmacological and Analytical information of combination of Metformin hydrochloride and Teneligliptin hydrobromide hydrate to researcher in development of combined dosage form.
How to cite this article: Patil M, Jani HD, Khoja SS, Pirani NA, Khoja S;A Review on chemistry and pharmacological activity of metformin hydrochloride and teneligliptin hydrobromide hydrate in combined dosage form; PharmaTutor; 2017; 5(3); 24-30
[ABSTRACT WITH CITATION] [VIEW AS HTML]
.png)
